Journals / The Journal of Breast Health / 2015 / Cilt: 11 - Sayı: 2

Meme Kanserli Bir Hastada Dokataksele Bağlı Gelişen Skleroderma

Docetaxel-induced Scleroderma in A Breast Cancer Patient: A Case Report

Pages
95–97
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

In this paper, we presented a 60-year-old female patient in whom scleroderma developed because docetaxel chemotherapy for breast cancer because it is encountered rarely.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Paclitaxel and docetaxel are antineoplastic drugs derived from the yew tree, Taxus brevifolia.
📊
Key Findings & Data:They are the members of the taxane family and act by inhibiting mitotic activity due to the suppression of microtubule depolymerization.
💡
Conclusion & Impact:In this paper, we presented a 60-year-old female patient in whom scleroderma developed because docetaxel chemotherapy for breast cancer because it is encountered rarely.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

Paclitaxel and docetaxel are antineoplastic drugs derived from the yew tree, Taxus brevifolia. They are the members of the taxane family and act by inhibiting mitotic activity due to the suppression of microtubule depolymerization. They are used in the treatment of ovarian cancer, breast cancer, gastric cancer, small cell lung cancer, and head and neck cancer. In addition to side effects such as cardiotoxicity, neutropenia, arthralgia, and myalgia, they may also cause alopecia, urticaria, mucositis, acral erythema, pustular dermatitis, erythema multiforme, and scleroderma-like mucocutaneous lesions. Scleroderma is among the uncommon side effects of taxane antineoplastic agents. As was the case in few cases in literature, it usually begins with edematous changes in the proximal aspect of the extremities, and subsequently, sclerosis is developed in the skin. Scleroderma, which usually regresses with the discontinuation of the drug and with steroid therapy, may lead to severe contractions that require physical therapy and rehabilitation in some patients. In this paper, we presented a 60-year-old female patient in whom scleroderma developed because docetaxel chemotherapy for breast cancer because it is encountered rarely.

Özet

Paklitaksel ve dokataksel, Taxus brevifolia denilen yew ağacından üretilen, mikrotübül depolimarizasyon supreyonu sonucu mitotik aktivitenin inhibisyonu ile etki gösteren, taksan ailesine mensup antineoplastik ilaçlardır. Over, meme, mide, küçük hücreli akciğer kanseri, baş ve boyun kanserlerinin tedavisinde kullanılmaktadır. Kardiotoksisite, nötropeni, artralji, miyalji gibi yan etkilerin dışında alopesi, ürtiker, mukozit, akral eritem, püstüler dermatit, eritema multiforme ve skleroderma benzeri mukokutanöz lezyonlara da neden olabilir. Skleroderma taksan grubu antineoplastik ilaçların sık görülmeyen yan etkilerindendir. Literatürdeki az sayıdaki olgularda olduğu gibi genellikle ekstremitelerin uç kısımlarında ödematöz değişiklik olarak başlar ve ardından ciltte skleroz gelişir. Çoğunlukla ilacı kesmek ve steroid tedavisi ile gerileyen skleroderma bazı hastalarda fizik tedavi ve rehabilitasyon gerektirecek kadar ciddi kontraktürlere neden olabilir. Bu yazımızda meme kanseri nedeniyle dokataksel kemoterapisi verilen 60 yaşındaki bayan hastada gelişen skleroderma olgusunu, nadir görülmesi nedeniyle, sunduk.

🔖

Cite This Article

KILIÇ, M. Ö., YALAZA, M., BİLGİÇ, C. İ., DENER, C. (2015). Meme Kanserli Bir Hastada Dokataksele Bağlı Gelişen Skleroderma. The Journal of Breast Health, Cilt: 11 - Sayı: 2, 95–97. https://ajindex.com/articles/362650

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (11)

  1. Mackey JR, Martin M, Pienkowski T, Rolski J, Guastalla JP, Sami A, Glaspy J, Juhos E, Wardley A,Fornander T, Hainsworth J, Coleman R, Modiano MR, Vinholes J, Pinter T, Rodríguez-Lescure A, Colwell B, Whitlock P, Provencher L, Laing K, Walde D, Price C, Hugh JC, Childs BH, Bassi K, Lindsay MA, Wilson V, Rupin M, Houé V, Vogel C
  2. TRIO/ BCIRG 001 investigators. Adjuvant docetaxel, doxorubicin, and cyclophosphamide in node-positive breast cancer: 10-year follow-up of the phase 3 randomised BCIRG 001 trial. Lancet Oncol 2013
  3. (PMID: 23246022) [CrossRef] 2. Martín M, Ruiz A, Ruiz Borrego M, Barnadas A, González S, Calvo L, Margelí Vila M, Antón A, Rodríguez-Lescure A, Seguí-Palmer MA, Muñoz-Mateu M, Dorca Ribugent J, López-Vega JM, Jara C, Espinosa E,Mendiola Fernández C, Andrés R, Ribelles N, Plazaola A, SánchezRovira P, Salvador Bofill J, Crespo C,Carabantes FJ, Servitja S, Chacón JI, Rodríguez CA, Hernando B, Álvarez I, Carrasco E, Lluch A. Fluorouracil, Doxorubicin, and Cyclophosphamide (FAC) Versus FAC Followed by Weekly Paclitaxel As Adjuvant Therapy for High-Risk, Node-Negative Breast Cancer: Results From the GEICAM/2003-02 Study. Clin Oncol 2013
  4. (PMID: 23733779) [CrossRef] 3. Cohen PR. Photodistributed erythema multiforme: paclitaxel-related, photosensitive conditions in patients with cancer. J Drugs Dermatol 2009
  5. (PMID: 19180897) 4. Dasanu CA, Alexandrescu DT. Systemic lupus erythematosus associated with paclitaxel use in the treatment of ovarian cancer. South Med J. 2008
  6. (PMID: 19088531) [CrossRef] 5. Moisidis C, Möbus V. Erythema multiforme major following docetaxel. Arch Gynecol Obstet 2005
  7. (PMID: 15243755) [CrossRef] 6. Chew L, Chuen VS. Cutaneous reaction associated with weekly docetaxel administration. J Oncol Pharm Pract 2009
  8. (PMID: 18753180) [CrossRef] 7. Battafarano DF, Zimmerman GC, Older SA, Keeling JH, Burris HA. Docetaxel (Taxotere) associated scleroderma-like changes of the lower extremities. A report of three cases. Cancer 1995
  9. (PMID: 8630861) [CrossRef] 8. Cleveland MG, Ajaikumar BS, Reganti R. Cutaneous fibrosis induced by docetaxel: a case report. Cancer. 2000
  10. (PMID: 10699898) [CrossRef] 9. Hassett G, Harnett P, Manolios N. Scleroderma in association with the use of docetaxel (taxotere) for breast cancer. Clin Exp Rheumatol. 2001
  11. (PMID: 11326485) 10. Gotaskie GE, Andreassi BF. Paclitaxel: a new antimitotic chemotherap